HUS 080-2024 Genetic testing for rare diseases, various methods
HUS Group · koko Suomi
Perustiedot
- Tarjousten määräaika
- to 6.3.2025 klo 12.00 (päättynyt)
- Kysymysten määräaika
- ke 12.2.2025 klo 12.00 (päättynyt)
- Toteutuspaikka
- koko Suomi
- Hankintalaji
- Palvelu
- Menettely
- Avoin menettely, EU-hankinta
- Ilmoituksen tyyppi
- Hankintailmoitus – SOTE- ja muut erityiset palvelut
- Arvioitu kokonaisarvo
- Ei ilmoitettu
- Erät
- 20 erää
- Pääasiallinen CPV
- 85145000 Lääketieteellisten laboratorioiden palvelut
- Julkaistu
- 17.1.2025
Ilmoituksen teksti
Alkuperäinen teksti Hilmasta, muuttamattomanaThe Procurement Entities HUS Group (later also ”HUS”) and ISLAB hereby requests tenders for genetic testing for rare diseases using various methods. The procurement includes the following tests:
1. Ataxia repeat analysis by NGS
2. Repeat expansion analysis (UGT1A1)
3. Repeat expansion analysis (CANVAS)
4. Repeat expansion analysis (MUC1)
5. Genetic testing for hereditary Alpha Tryptasemia
6. MLH1 promoter methylation analysis
7. Beckwith-Wiedemann syndrome testing
8. Cystic fibrosis (CF-EU2)
9. Long-range PCR analysis of CYP21A2
10. Long-range PCR analysis of PKD1 and PKD2
11. Long-range PCR analysis of PMS2
12. Long-range PCR analysis of SBDS
13. Genetic testing for facioscapulohumeral muscular dystrophy (FSHD1 and FSHD2)
14. Chromosomal breakage test (Fanconi anemia)
15. Relative telomere length analysis
16. X inactivation test
17. Genetic testing for haemoglobinopathies
18. Germline episignature, DNA methylation pattern testing for specific genetic disorders
19. Sanger sequencing/ Long-range PCR analysis of the VWF gene
20. Retinoblastoma genetic screening.
The procurement is divided into lots so that each test is an independent part of the procurement. A tenderer may submit a tender for one or more lots. Two (2) tenderers will be selected as the service providers for each lot if that number of tenders meeting the requirements are received. The service providers shall be chosen based on the award criteria stated in this notice.
In addition to the lots described above, the tenderer may, if desired, offer other genetic tests as a voluntary option under the conditions described in this call for tenders.
The subject-matter of the procurement and the mandatory requirements of it are described in detail in this call for tenders and in its attachments.
A separate contract shall be conducted in writing with each chosen service provider after this tender procedure. The terms of the contract follow the terms stipulated in this call for tenders. The contract will continue until terminated.
Erien kuvaukset
Erä 1: Ataxia repeat analysis by NGS
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 2: Repeat expansion analysis (UGT1A1)
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 3: Repeat expansion analysis (CANVAS)
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 4: Repeat expansion analysis (MUC1)
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 5: Genetic testing for hereditary Alpha Tryptasemia
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 6: MLH1 promoter methylation analysis
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 7: Beckwith-Wiedemann syndrome testing
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 8: Cystic fibrosis (CF-EU2 test)
The CF-EU2 test. The sequencing of the entire coding region of the sample can be offered as an option.
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 9: Long-range PCR analysis of CYP21A2
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 10: Long-range PCR analysis of PKD1 and PKD2
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 11: Long-range PCR analysis of PMS2
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 12: Long-range PCR analysis of SBDS
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 13: Genetic testing for facioscapulohumeral muscular dystrophy (FSHD1 and FSHD2)
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 14: Chromosomal breakage analysis (Fanconi anemia)
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 15: Relative telomere length analysis
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 16: X inactivation test
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 17: Genetic testing for haemoglobinopathies
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 18: Germline episignature, DNA methylation pattern testing for specific genetic disorders
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 19: Sanger sequencing/ Long-range PCR analysis of the VWF gene
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erä 20: Retinoblastoma genetic screening
The requirements for the tests are described in the service depiction attached to this call for tenders.
Erät
| Erä | Nimi | Ammattiala | Arvioitu arvo | CPV |
|---|---|---|---|---|
| 1 | Ataxia repeat analysis by NGS | – | – | 85148000 |
| 2 | Repeat expansion analysis (UGT1A1) | – | – | 85148000 |
| 3 | Repeat expansion analysis (CANVAS) | – | – | 85145000 |
| 4 | Repeat expansion analysis (MUC1) | – | – | 85145000 |
| 5 | Genetic testing for hereditary Alpha Tryptasemia | – | – | 85145000 |
| 6 | MLH1 promoter methylation analysis | – | – | 85145000 |
| 7 | Beckwith-Wiedemann syndrome testing | – | – | 85148000 |
| 8 | Cystic fibrosis (CF-EU2 test) | – | – | 85148000 |
| 9 | Long-range PCR analysis of CYP21A2 | – | – | 85145000 |
| 10 | Long-range PCR analysis of PKD1 and PKD2 | – | – | 85148000 |
| 11 | Long-range PCR analysis of PMS2 | – | – | 85148000 |
| 12 | Long-range PCR analysis of SBDS | – | – | 85145000 |
| 13 | Genetic testing for facioscapulohumeral muscular dystrophy (FSHD1 and FSHD2) | – | – | 85145000 |
| 14 | Chromosomal breakage analysis (Fanconi anemia) | – | – | 85145000 |
| 15 | Relative telomere length analysis | – | – | 85145000 |
| 16 | X inactivation test | – | – | 85148000 |
| 17 | Genetic testing for haemoglobinopathies | – | – | 85148000 |
| 18 | Germline episignature, DNA methylation pattern testing for specific genetic disorders | – | – | 85145000 |
| 19 | Sanger sequencing/ Long-range PCR analysis of the VWF gene | – | – | 85148000 |
| 20 | Retinoblastoma genetic screening | – | – | 85148000 |
Hankinnan vaiheet
-
Hankintailmoitustämä ilmoitus
Tarjouspyyntö julkaistiin, määräaika 6.3.2025 klo 12.00.
-
Voittajat: Centogene GmbH ja MVZ Martinsried GmbH.